Loading
CCN2 (CCN family member 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Is involved in the stimulation of osteoblast differentiation and has a critical role in osteogenesis.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · CCN2 (CCN family member 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
CCN2 (CCN family member 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes.
No product in this corpus aims at CCN2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CCN2: RNA tissue enhanced (blood vessel 1,230 nTPM); blood lineage lineage enriched (B-cells 8 nTPM); high antibody staining in 3 normal tissues; highest cancer staining endometrial cancer (7 of 11 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas CCN2 tissue; Open Targets ENSG00000118523 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Bradham D.M. et al, J. Cell Biol, 1991, "Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10". Source.
Sources: HGNC HGNC:2500 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P29279 (protein name, function text, keywords and locations (REST API)); CIViC gene CCN2 (1 evidence items, 0 assertions, 1 variants; diseases: Glioma (GraphQL API, CC0))
Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Is involved in the stimulation of osteoblast differentiation and has a critical role in osteogenesis. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis. Location: Secreted, extracellular space, extracellular matrix; Secreted (UniProt). Locus 6q23.2 (HGNC).
RNA: tissue enhanced (blood vessel 1,230 nTPM), detected in all normal tissues. Blood: lineage enriched (B-cells 8 nTPM).
Medium: Adrenal gland, Cerebral cortex, Cervix, Duodenum, Liver, Lung, Lymph node, Oral mucosa.
Medium only: melanoma, testis cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CCN2" OR ABSTRACT:"CCN2" OR TITLE:"cellular communication network factor 2" OR ABSTRACT:"cellular communication network factor 2" OR TITLE:"CCN family member 2" OR ABSTRACT:"CCN family member 2" OR TITLE:"IGFBP8" OR ABSTRACT:"IGFBP8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CCN2, not a curated reading list.